NAPPA names initial advisory board across four pillars
The inaugural advisory board spans Science, Drug R&D, Industry Translation, and Capital — the four dimensions NAPPA considers essential for cross-border execution.
NAPPA has announced its initial advisory board, structured around the four pillars the alliance considers indispensable for translating cross-border partnerships into outcomes.
The four pillars and inaugural advisors
Science — Xumu Zhang Professor and Dean of the Medi-X Institute at Southern University of Science and Technology (SUSTech). One of the world’s leading scientists in asymmetric catalysis, with 400+ publications, 25,000+ citations, and 50+ international patents.
Drug R&D — Dr. Mann Fung Former CEO of Tavotek Biotherapeutics, former VP at Johnson & Johnson where he helped develop the BTK inhibitor Ibrutinib, with senior oncology roles at Eli Lilly.
Capital (China) — Qin Chao Lu Founding Partner and Chairperson of Danlu Capital, managing approximately 2 billion RMB in healthcare investments. Former Partner at Sequoia Capital China for 13 years.
Capital (Cross-Border US-China) — Xin Sylvia He, PhD Managing Partner at Hyfinity Investments. Former Senior Partner at CDH Investments. PhD in Immunobiology from Yale.
What truly determines a platform’s ceiling is never just a title, but whether scientific capability, industry experience, and capital acumen simultaneously coexist.
Additional advisors across each pillar will be announced through the year.